Intellia – View full story
This author has not written his bio yet.
But we are proud to say that nacnkcell contributed 44 entries already.
Entries by nacnkcell
Allan Reine joins the Board as independent Non-Executive Director Brings significant experience as CFO of NASDAQ-listed biotechs, where he helped raise over $700 million Over 20 years in the biotechnology industry with relevant experiences as a biotech CFO, portfolio management, sell-side analyst and investment banking Galway, Ireland and San Diego, USA, 23 March 2022 – […]
Labiotech – View full story
Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell therapies ONK is responsible for the research, clinical development and […]
Endpoints News – View full story
Fierce Biotech – View full story
The Pharma Letter – View full story
BioPharma Dive – View full story
BioSpace – View full story
The Irish Times – View full story